Sign In
Buy BSX
$47.69
+0.0100 (+0.0210%)
At Close: Jun 03, 2026
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
12:50pm, Tuesday, 19'th Oct 2021
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
10:58am, Tuesday, 12'th Oct 2021
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
12:17pm, Monday, 11'th Oct 2021
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
This Stock Is Likely To Outperform Boston Scientific
07:30am, Thursday, 07'th Oct 2021
We think that Stryker stock (NYSE: SYK) currently is a better pick compared to Boston Scientific stock, despite Stryker being slightly more expensive of the two. Stryker trades at about 6.4x trailing
Why Boston Scientific (BSX) Is Buying Baylis Medical For $1.75 Billion
10:09pm, Wednesday, 06'th Oct 2021
Boston Scientific Corporation (NYSE: BSX) has announced that it has entered into a definitive agreement to buy Baylis Medical Company for an upfront payment of $1.75 billion. These are the details.
Boston Scientific's Eluvia Drug-Eluting Vascular Stent Tops Bare Metal Stents
03:38pm, Wednesday, 06'th Oct 2021
Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting. Data presented inclu
Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
12:35pm, Wednesday, 06'th Oct 2021
LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia ste
Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal
08:37am, Wednesday, 06'th Oct 2021
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion. The acquisition will expand Boston Scientific's electrophysiolog
Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism
07:15am, Wednesday, 06'th Oct 2021
Boston Scientific Corporation (NYSE: BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting. Related: Boston Scientific Acquires Pro
Boston Scientific to acquire Baylis Medical Co. for $1.75 billion
07:08am, Wednesday, 06'th Oct 2021
Boston Scientific Corp. BSX, +0.07% said Wednesday it has entered an agreement to acquire Baylis Medical Co. Inc. for an upfront payment of $1.75 billion. The deal will "expand the Boston Scientific e
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.
07:00am, Wednesday, 06'th Oct 2021
MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for a
Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21
04:21pm, Tuesday, 05'th Oct 2021
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-brea
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon
12:35pm, Tuesday, 05'th Oct 2021
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clini
Boston Scientific Announces Conference Call Discussing Third Quarter 2021 Results
10:30am, Monday, 04'th Oct 2021
MARLBOROUGH, Mass., Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
11:08am, Thursday, 30'th Sep 2021
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
